G1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation Summit
22 Mayo 2024 - 9:00AM
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology
company, today announced that G1’s Chief Medical Officer Dr. Raj
Malik and Chief Commercial Officer Andrew Perry will participate in
a fireside chat at TD Cowen’s 5th Annual Oncology Innovation
Summit: Insights for ASCO & EHA, on Wednesday, May 29, at
8:30AM EDT.
The webcast of the event will be accessible on the Events &
Presentations page of http://www.g1therapeutics.com.
About G1 TherapeuticsG1 Therapeutics, Inc. is a
commercial-stage oncology biopharmaceutical company whose mission
is to develop and deliver next-generation therapies that improve
the lives of those affected by cancer, including the Company’s
first commercial product, COSELA® (trilaciclib). The Company is
also evaluating therapies in combination with cytotoxic therapies
and/or immunotherapy in areas of high unmet need including
triple-negative breast cancer and extensive stage small cell lung
cancer. G1’s goal is to provide innovative therapeutic advances for
people living with cancer. G1 is based in Research Triangle Park,
N.C. For additional information, please visit
http://www.g1therapeutics.com and follow us on X (formerly known as
Twitter) @G1Therapeutics and LinkedIn.
G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and
the COSELA logo are trademarks of G1 Therapeutics, Inc.
Contacts:Will RobertsCommunications OfficerVice
President, Investor Relations and Corporate Communications(919)
907-1944 wroberts@g1therapeutics.com
G1 Therapeutics (NASDAQ:GTHX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
G1 Therapeutics (NASDAQ:GTHX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024